Article Versions Notes

Xu T, Schulga A, Konovalova E, Rinne SS, Zhang H, Vorontsova O, Orlova A, Deyev SM, Tolmachev V, Vorobyeva A. Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin–Toxin Fusion in a Pancreatic Cancer Xenograft Model. International Journal of Molecular Sciences. 2023; 24(3):2838. https://doi.org/10.3390/ijms24032838

Xu, Tianqi, Alexey Schulga, Elena Konovalova, Sara S. Rinne, Hongchao Zhang, Olga Vorontsova, Anna Orlova, Sergey M. Deyev, Vladimir Tolmachev, and Anzhelika Vorobyeva. 2023. "Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin–Toxin Fusion in a Pancreatic Cancer Xenograft Model" International Journal of Molecular Sciences 24, no. 3: 2838. https://doi.org/10.3390/ijms24032838

Xu, T., Schulga, A., Konovalova, E., Rinne, S. S., Zhang, H., Vorontsova, O., Orlova, A., Deyev, S. M., Tolmachev, V., & Vorobyeva, A. (2023). Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin–Toxin Fusion in a Pancreatic Cancer Xenograft Model. International Journal of Molecular Sciences, 24(3), 2838. https://doi.org/10.3390/ijms24032838